BACKGROUND: Enteral nutritional therapy (ENT) is the best route for the nutrition of critically ill patients with improved impact on the clinical treatment of such patients. OBJECTIVE: To investigate the energy and protein supply of ENT in critically ill in-patients of an Intensive Care Unit (ICU). METHODS: Prospective longitudinal study conducted with 82 critically ill in-patients of an ICU, receiving ENT. Anthropometric variables, laboratory tests (albumin, CRP, CRP/albumin ratio), NUTRIC-score and Nutritional Risk Screening (NRS-2002), energy and protein goals, and the inadequacies and complications of ENT were assessed. Statistical analysis was performed using the Chi-square or Fischer tests and the Wilcoxon test. RESULTS: A total of 48.78% patients were at high nutritional risk based on NUTRIC score. In the CRP/albumin ratio, 85.37% patients presented with a high risk of complications. There was a statistically significant difference (P<0.0001) for all comparisons made between the target, prescription and ENT infusion, and 72% of the quantities prescribed for both calories and proteins was infused. It was observed that the difference between the prescription and the infusion was 14.63% (±10.81) for calories and 14.21% (±10.5) for proteins, with statistically significant difference (P<0.0001). In the relationship between prescription and infusion of calories and proteins, the only significant association was that of patients at high risk of CRP/albumin ratio, of which almost 94% received less than 80% of the energy and protein volume prescribed (P=0.0111). CONCLUSION: The administration of ENT in severely ill patients does not meet their actual energy and protein needs. The high occurrence of infusion inadequacies, compared to prescription and to the goals set can generate a negative nutritional balance.

Cachexia syndrome has been estimated to be responsible for the death of a significant amount of cancer patients. It is characterized mainly by reduced intake, systemic inflammation and anomalous metabolism. Progressive loss of body weight, muscle wasting and functional impairment are remarkable features of the entity. Muscle wasting is due to a combination of both a diminution of protein synthesis and an increase in protein degradation. Progressive reduction of muscle protein drives to muscle fibre lessening and a reduction in its cross sectional area. Likewise, there is some evidence that a specific type of fiber is targeted in this setting. Defined cut points for sarcopenia are essential to diagnose skeletal muscle depletion and various methods have been carried out. The ubiquitin-proteasome pathway seems to play the main role in the breakdown of myofibrillar proteins. The trend to lose muscle in cancer cachexia patients may be associated to the triggering of catabolic signals by pro-inflammatory cytokines or tumour-specific agents such as proteolysis-inducing factor. Regarding prognostication, mortality risk is documented in sarcopenic cancer patients but is particularly accentuated in sarcopenic obese ones. A relationship between severe muscle depletion and survival has been shown in patients with different types of cancer such us pancreas, lung, biliary tract and colorrectal cancer. Therapeutic interventions for cancer cachexia syndrome are likely to require treatments from various groups including a combination of nutritional support, drugs with orexigenic, anabolic, anti-inflammatory effects and also non-pharmacologic interventions such as exercise. El músculo, elemento clave para la supervivencia en el enfermo neoplásico Muscle wasting as a key predictor of survival in cancer patients

No abstract